Skip to main content

Current Lecture Season

Base editing: chemistry on a target nucleotide in the genome of living cells

September 5, 2018 - 3:00pm to 4:00pm
David R. Liu, Ph.D. , Broad Institute of Harvard and MIT

Dr. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries.

Understanding the source of regenerative ability in animals

October 10, 2018 - 3:00pm to 4:00pm
Alejandro Sánchez Alvarado, Ph.D. , Stowers Institute for Medical Research

Salamanders and starfish might be “simpler” than humans, but they far surpass us in one major way—the ability to regenerate tissues and regrow lost limbs. Dr. Sánchez Alvarado studies regeneration using the flatworm planaria Schmidtea mediterranea. Remarkably, when halved or quartered (even by high school students) this organism can clone itself from the pieces. More than 100 years ago, that feat captured the attention of geneticist Thomas Hunt Morgan, who studied planarians years before his famed work on fruit flies. 

Genes controlling sleep and circadian rhythms

October 17, 2018 - 3:00pm to 4:00pm
Michael W. Young, Ph.D. , The Rockefeller University

The Young lab studies 24-hour circadian clocks, which time the recurring, daily activities observed in most organisms. These cellular clocks are active in most animal tissues and establish daily rhythms in physiology and behavior. The lab’s findings have implications for sleep and mood disorders as well as for dysfunctions related to the timing of gene activities underlying visual functions, locomotion, metabolism, immunity, learning, and memory.

Travelling through tissues one cell at a time: the Human Cell Atlas and barrier tissues

October 31, 2018 - 3:00pm to 4:00pm
Sarah Teichmann, Ph.D. , Wellcome Sanger Institute

Dr. Teichmann's group seeks to elucidate general principles of gene expression and protein complex assembly. Her lab is trying to understand how changes in cell state are regulated at the transcriptomic and epigenetic levels by studying the differentiation of mouse T helper (Th) cells and embryonic stem cells (mESC) at the single cell level. Her lab uses and develops both computational and experimental approaches in the field of single cell genomics to address our questions.

What makes America great

November 7, 2018 - 3:00pm to 4:00pm
William A. Gahl, M.D., Ph.D. , National Human Genome Research Institute

Dr. Gahl studies the natural history, diagnosis, and treatment of rare genetic disorders such as cystinosis, Hermansky-Pudlak Syndrome, sialic acid storage diseases, GNE myopathy, and disorders of platelets and pigmentation. He also investigates undiagnosed disorders under the aegis of the NIH Undiagnosed Diseases Program and Network, and pursues new disease discovery.

Endoplasmic reticulum and immunometabolic homeostasis

November 13, 2018 - 3:00pm to 4:00pm
Gokhan S. Hotamisligil, M.D., Ph.D. , Harvard T.H. Chan School of Public Health

The major interest of Dr. Hotamisligil's laboratory is to study the regulatory pathways, which control glucose and lipid metabolism. His lab's biochemical and genetic studies focus on signal transduction using cultured mammalian cells as well as transgenic animals to identify specific abnormalities in these pathways, which are involved in human metabolic and inflammatory diseases including obesity, diabetes, fatty liver disease, atherosclerosis, and asthma.

Standing on the shoulders of mice: adventures in human immunology

November 14, 2018 - 3:00pm to 4:00pm
Mark M. Davis, Ph.D. , Stanford University

While inbred mice have been a very powerful model for analyzing the immune system, recent advances, both technological and conceptual, have begun to make direct studies of the human immune system possible. This is vitally important from a translational perspective, as mouse models of disease have not been as productive as hoped for in producing “actionable intelligence” with which to diagnose and treat patients.

Senescence: live fast, die young, and leave a good-looking corpse

November 28, 2018 - 3:00pm to 4:00pm
Norman E. Sharpless, M.D. , National Cancer Institute

In addition to serving as director of NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. Dr. Sharpless has made seminal contributions to the understanding of the relationship between aging and cancer, and in the preclinical development of novel therapeutics for melanoma, lung cancer, and breast cancer.

Can you catch dementia? Insights and solutions from prion disease

December 6, 2018 - 2:00pm to 3:00pm
John Collinge, M.D. , University College London

Professor Collinge leads a highly multidisciplinary research unit dedicated to understanding prion diseases. Prions are notorious “protein-only” infectious agents devoid of genes which cause invariably fatal brain diseases following silent incubation periods which may span a human lifetime. The diseases can arise spontaneously, by infection or be inherited. Remarkably, prions are composed of a cloud of self-propagating assemblies of a misfolded cellular protein that can encode information, generate neurotoxicity and evolve and adapt in vivo.

Of mice and men: what we can learn about human cancer by studying mouse models

December 19, 2018 - 3:00pm to 4:00pm
Cory Abate-Shen, Ph.D. , Columbia University Irving Medical Center

The research in Cory Abate-Shen’s laboratory is focused on understanding basic mechanisms of transcriptional regulation and differentiation, and how these become dysregulated in cancer. The laboratory takes a multi-disciplinary approach to investigate genitourinary malignancies, which includes using mechanism-based studies, analyses of genetically-engineered mouse models (GEMMs), and state-of-the-art systems biology approaches.


The page was last updated on Wednesday, June 11, 2014 - 4:07pm